MNPRMonopar Therapeutics
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$17M
- 3.4% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear-287% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | |
| Operating income | −$9M | −$11M | −$9M | −$16M | −$17M | 3.4% |
| Net income | −$9M | −$11M | −$8M | −$16M | −$14M | 12% |
| Operating cash flow | −$7M | −$7M | −$8M | −$6M | −$12M | 91% |
| Stock-based comp | $1M | $2M | $2M | $1M | $5M | 324% |
| Buybacks | — | — | — | $0 | $35M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 7
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $11M | $17M | 3839 | — |
| FY2024 | $1M | $2M | 186 | — |
| FY2023 | $2M | −$166K | 14 | — |